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Themost frequent form of hemolytic-uremic syndrome (HUS) is associatedwith infections
caused by Shiga-like toxin-producing Enterohaemorrhagic Escherichia coli (STEC). In
rarer cases HUS can be triggered by Streptococcus pneumoniae. While production
of Shiga-like toxins explains STEC-HUS, the mechanisms of pneumococcal HUS are
less well-known. S. pneumoniae produces neuraminidases with activity against cell
surface sialic acids that are critical for factor H-mediated complement regulation on
cells and platelets. The aim of this study was to find out whether S. pneumoniae
neuraminidase NanA could trigger complement activation and hemolysis in whole blood.
We studied clinical S. pneumoniae isolates and two laboratory strains, a wild-type
strain expressing NanA, and a NanA deletion mutant for their ability to remove sialic
acids from various human cells and platelets. Red blood cell lysis and activation of
complement was measured ex vivo by incubating whole blood with bacterial culture
supernatants. We show here that NanA expressing S. pneumoniae strains and isolates
are able to remove sialic acids from cells, and platelets. Removal of sialic acids by
NanA increased complement activity in whole blood, while absence of NanA blocked
complement triggering and hemolytic activity indicating that removal of sialic acids by
NanA could potentially trigger pHUS.
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INTRODUCTION
Streptococcus pneumoniae infection is a major cause of morbidity andmortality worldwide. Despite
the current vaccination program it kills approximately half a million children under 5 years of age
worldwide every year. It typically causes diseases such as otitis media, pneumonia, bacteremia, and
meningitis. Pneumococcal atypical hemolytic uremic syndrome (pHUS) is a rare complication of
an invasive pneumococcal infection that mainly affects young children (Waters et al., 2007). S.
pneumoniae is known to express neuraminidases, NanA, NanB, and NanC that can remove sialic
acids from cell surfaces (Burnaugh et al., 2008). Of these, nanA and nanB genes are present in
almost all clinical S. pneumoniae isolates while nanC is present in ∼50% of isolates (Pettigrew
et al., 2006). Removal of sialic acids from cell membrane glycostructures also reduces binding of
complement regulator factor H to self-cell surfaces (Nissila et al., 2018). This may lead to a defect in
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complement regulation on autologous cells similarly as in a rare
form of HUS called atypical HUS (aHUS) (Szilagyi et al., 2013;
Jokiranta, 2017).
The complement system is composed of more than 40
soluble and cell surface anchored proteins (Sarma Ward and
Ward, 2011). It targets microbes and damaged self-cells via
recognition of foreign or exposed self-antigens by antibodies
(classical) or carbohydrate recognizing lectins (lectin pathway),
or by spontaneous hydrolysis of C3 (alternative pathway, AP)
(Jokiranta, 2017). All three pathways lead to opsonization of the
target surface by C3b, generation of chemotactic fragments, C3a
and C5a, and formation of membrane attack complexes (MAC,
C5b-9) that can directly lyse the target (Sarma Ward and Ward,
2011). Because C3b can deposit on any biological surface, it can
also deposit on the host’s own cells. Therefore, strict regulation of
its activation is essential.
Factor H is a key regulator of the AP. It is composed of
20 domains from which domains 5–7 bind C-reactive protein,
apolipoprotein E, and negatively charged polyanions like heparin
7 (Blackmore et al., 1996; Giannakis et al., 2003; Haapasalo
et al., 2015) while domains 1–4 and 19–20 bind to C3b. The
C-terminal domains 19–20 mediate simultaneous binding to
deposited C3b and cell surface sialic acids (Kajander et al.,
2011). Factor H recognizes α2–3 linked N-terminal sialic acid
glycans that are found abundantly on various human cells
(Blaum et al., 2015). These interactions explain factor H-
mediated discrimination between self and non-self cells. The
importance of factor H-mediated self-surface recognition is
exemplified by the development of aHUS when mutations in
factor H or anti-factor H autoantibodies disturb the domain
19–20 mediated interaction with sialic acids and/or C3b
(Hyvarinen et al., 2016).
The aHUS-associated mutations in domains 19–20 of factor
H significantly reduce the interaction between factor H and
sialic acids on red blood cells, endothelial cells, and platelets
(Hyvarinen et al., 2016). This partially explains the molecular
mechanism behind the severe endothelial cell damage caused
by FH mutations in aHUS. Most aHUS cases can be explained
by mutations in complement genes or autoantibodies against
factor H. However, ∼40% of aHUS cases do not have an
explanation (Noris et al., 2014). Many of these secondary HUS
cases are caused by infections with microbes other than Shiga-
like toxin-producing Enterohemorrhagic E. coli (STEC) such
as influenza virus and S. pneumoniae (Szilagyi et al., 2013;
Bitzan and Zieg, 2017).
The present study was set up to investigate, whether
removal of cell surface sialic acids by S. pneumoniae NanA
could play a role in triggering pHUS. We show here that
the presence of NanA in S. pneumoniae culture supernatant
removes sialic acids from various cell types. The release
of sialic acid residues increases hemolysis and complement
activation in whole blood and activates platelets as well.
The presence of NanA in whole blood and in the presence
complete microbial secretome suggests a significant role for
NanA in uncontrolled complement-mediated hemolysis and
platelet aggregation.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Preparation of S. pneumoniae strains D39 wt and D39 1nanA
(serotype 2) have been described (King et al., 2004). Isolates
1, 2, and 3 were S. pneumoniae serotype two strains isolated
from a blood culture of septic patients with the permission
of the ethical review board of the Hospital District of
Helsinki and Uusimaa, Finland (448/13/03/00/09). Bacteria
were grown in Todd Hewitt Broth (THB) in 5% CO2 at
37◦C until late log-phase (OD620 ∼0.7) and centrifuged at
3,000 × g for 10min. Supernatants were filtered through
0.45µm filters (Nalgene, Rochester, NY, US) and stored
at−80◦C.
Proteins
Neuraminidase from Clostridium perfringens (defined as
Neu in the manuscript) was purchased from New England
Biolabs (Ipswich, MA, US). The recombinant NanA
neuraminidase (defined as RecNanA in the manuscript)
containing only the catalytic region (aa303-777) of S.
pneumoniae NanA (SP_1693) was expressed with N-
terminal 6xHis tag. The DNA was amplified using forward
AAGTTCTGTTTCAGGGCCCGCCTGAAGGAGCGGCTTTAAC
and reverseATGGTCTAGAAAGCTTTAATTTTTGCTCAAAAAT
TCCCA primers and cloned in pOPINF vector. For expression
plasmids were transformed in E. coli Rosetta DE3 cells.
Four hundred milliliter of LB with 100µg/ml ampicillin was
inoculated with 8ml of overnight culture grown in LB ampicillin.
Cells were grown to OD600 ∼0.8 at 37◦C with shaking and
afterward culture was transferred to 25◦C and grew overnight.
Cells were harvested and resuspended in 20ml of binding buffer
(20mM Sodium phosphate buffer, pH 7.4, 5mM imidazole,
500mM NaCl, 5mM β-mercaptoethanol) and lysed using
French press. Supernatant was collected by centrifugation at
30,000 × g for 30min at 4◦C. Protein was allowed to bind
to ProBond Ni-NTA agarose (Invitrogen) for 45min at 4◦C.
Column was washed with binding buffer containing 20mM
imidazole and eluted in 8ml of elution buffer (binding buffer
with 300 mM imidazole).
Cell Culture
Human embryonic kidney cells (HEK293T) were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal bovine serum, penicillin, streptomycin, and L-
glutamine (Gibco, Waltham, MA, US) as described (Haapasalo
et al., 2018). Human umbilical endothelial cells (HUVECs)
were cultured in EndoGRO-LS media (Millipore, Burlington,
MA, US) as described (Hyvarinen et al., 2016) and passaged
≤6 in our assays. ATCC U937 human monocytic cells
were obtained as a kind gift from Dr. Carla de Haas
(UMCU, Netherlands) and cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium (Gibco, Waltham, MA, US)
supplemented with penicillin, streptomycin and 10% (v/v) fetal
bovine serum.
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(MUAN) sodium salt hydrate (Sigma, St. Louis, MI, US)
was used to measure the activities of RecNanA (at 10 nM
concentration), Neu (at 110 nM final concentration), and
supernatants (10µl) from S. pneumoniae strains D39 wt and D39
1nanA and the clinical isolates. Briefly a 0.2% solution of MUAN
(2
′
-(4 –methyl-umbelliferyl) α-D-N-acetylneuraminic acid) was
made in 0.25M Sodium acetate buffer pH 7. Pure proteins or
culture supernatants were mixed with 10 µl of MUAN and
incubated at 37◦C for 5min. 1.5ml of sodium carbonate buffer
pH 9.6 was added and mixed. Two hundred microliter of the
mixture was placed in a black well-microtitre plate (NUNC)
for 1 s reading at 355 nm/460 nm with a 5 s shake of the plate.
Negative control used was reaction using media but no bacterial
cells or 150mM phosphate buffered saline (pH 7.4) (PBS).
A modified thiobarbituric acid assay was used to analyze the
released sialic acids from cell surfaces as previously described
(Warren, 1959). Mammalian cells were incubated with 10% (v/v)
bacterial supernatant for 30min at 37◦C in RPMI supplemented
with 0.05% human serum albumin (RPMI-HSA) (Sigma). The
pelleted supernatant (300 × g for 10min) from this reaction was
oxidized by addition of 1ml sodium arsenate (10% wt/vol) in
0.5M sodium sulfate/0.05M H2SO4 (Sigma). The chromophore
was developed by addition of 3ml of 2-thiobarbituric acid (0.6%
wt/v) in 0.5M sodium sulfate (Sigma). Samples were boiled at
100◦C for 10min and rapidly cooled. The sample was mixed
1:1 with acid butanol (5% v/v) (Sigma) and free sialic acid was
measured at OD 549/OD 532 nm.
Analysis of Sialic Acids From
Neuraminidase Treated Cells
HEK cells (5 × 106 cells/ml) were incubated with 10% (v/v) S.
pneumoniae culture supernatant for 30min at 37◦C in round
bottom 96-Well polystyrene plates (Nunc, Roskilde, Denmark)
in RPMI-HSA and centrifuged at 300 × g for 10min at
4◦C. Maackia Amurensis Lectin II (MAL-II) (Vector Labs,
Burlingame, CA, US) was labeled with NT-647 dye following
the instructions provided (NanoTemper, München, Germany).
Washed cells were incubated with 45 nM NT-647 labeled MAL-
II for 45min at 4◦C. Cells were washed by centrifugation and
fixed with 1% (v/v) paraformaldehyde (Thermo Fisher Scientific,
Waltham,MA, US) in RPMI-HSA. Events were acquired with BD
LSR Fortessa flow cytometer (Laser 640 nm, filter 670/30) and
analyzed using FlowJo 10.1r5 (FlowJo LLC, Ashland, Oregon).
Gating of the cells was done with forward scatter (FSC) and side
scatter (SSC) to find viable, single cell events.
For peripheral blood monocytic cell, erythrocyte, and
platelet assays blood was drawn to hirudin (Roche Diagnostics,
Mannheim, Germany) or citrate tubes from healthy human
volunteers after informed written and signed consent (Ethical
Committee decision 406/13/03/00/2015, Hospital district of
Helsinki and Uusimaa). Blood was diluted 1:1 with PBS and
then incubated 1:1 with S. pneumoniae culture supernatant in
round bottom polystyrene tubes (Corning Inc., NY, US) in an
orbital rotator for 1 h at 37◦C. Next, cells and platelets were
isolated by centrifugation through a gradient (Histopaque 1.119
and 1.077; Sigma-Aldrich) as previously described (Nissila et al.,
2018). Cell, erythrocyte and platelet layers were collected in
separate tubes, washed once with RPMI-HSA and diluted to
RPMI-HSA. Cells (5 × 106 cells/ml) or platelets were incubated
with 45 nM of NT-647 labeled MAL-II lectin similarly as
described above.
Analysis of Galactose From Neuraminidase
Treated Cells
Fluorescein-labeled lectin from Arachis hypogaea (Peanut
agglutinin) (FITC-PNA) (Sigma-Aldrich, St. Louis, MI, US)
was used to analyze exposed galactose on the neuraminidase
treated cells. Cells were treated with S. pneumoniae recombinant
neuraminidase (RecNanA) in RPMI-HSA. Cells were pelleted
at 300 × g for 10min at 4◦C, the pellet was resuspended in
RPMI-HSAmedium and incubated with FITC-PNA. Events were
recorded with BD LSR Fortessa (laser 525/50).
Platelet Activation and Platelet
Aggregation Assays
Blood was collected in citrate tubes (BD Vacutainer R©, Franklin
Lakes, NJ, US), diluted with PBS in 1:1 volume and incubated
with S. pneumoniae supernatant (1:1 volume) and for 60min
at 37◦C. After centrifugation at 200 × g, 20min at room
temperature (acceleration = 0, brake= 0). Platelet-rich plasma
was collected in citrate buffer (9.4mM citrate, 4.8mM citric
acid, 17.4mM dextrose, 145mM NaCl, pH 6.5) and washed
twice at 440 × g (20min, room temperature, acceleration = 0,
brake = 0). After wash platelet-rich plasma was resuspended
in modified Tyrode’s buffer (137mM NaCl, 2.7mM KCl, 1mM
MgCl2, 7mM HEPES, 0.35% BSA, 5.5mM dextrose, 2mM
CaCl2, pH 7.4). Platelets were activated by adding hirudin plasma
from the same donor (33% v/v) and incubated 15min at 37◦C.
Activation was blocked by adding citrate buffer. Plasma was
removed by centrifugation as before. Pellet was resuspended and
stained with PeCy5 labeled antiCD62p (BioLegend, San Diego,
CA, US) and FITC labeled CD41a (Invitrogen, Carlsbad, CA,
US) for 10min at room temperature. Events were recorded
with BD LSR Fortessa (laser 670/30) and analyzed with
FlowJo 10.1r5.
Aggregation assay was modified from a previously
published protocol (Hyvarinen and Jokiranta, 2015). Platelet
suspension was prepared in modified Tyrode’s buffer (200 ×
106 particles/ml). Supernatants from S. pneumoniae strains
were added to the platelets (10 % V/V) and incubated at
room temperature for 10min in 96-well black clear-bottom
microplates (Perkin Elmer). Absorbance at 405 nm was recorded
immediately in Hidex Sense Microplate Reader for single
particles (double orbital shaking mode 120 rpm, 26◦C, 30 s
intervals, 10min incubation). Hirudin plasma from the same
individual was added 17% (V/V) and further absorbance 405 nm
reading was made.
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Hemolysis Measurements and
Complement Activation in Whole Blood
S. pneumoniae culture supernatants (1:1 volume) were incubated
with hirudin anticoagulated blood as described above. After
incubation the samples were centrifuged for at 300 × g
for 20min at 22◦C to separate the plasma. Hemolysis was
measured from the 1:1 PBS diluted plasma by observing
release of hemoglobin at 405 nm. To analyze the complement
activation levels separated plasma was supplemented with
10mM of EDTA to stop further complement activation
and stored at −20◦C. Soluble C5b-9 concentrations were
measured from the serially diluted plasma using MicroVue
C5b-9Plus EIA kits (Quidel, San Diego, CA), according to the
manufacturer’s instructions.
Factor H Removal Assay
To examine if recNanA could remove cell surface bound Factor
H, 300 µl of the U937 cells at 5 × 106 cells/ml concentration
in RPMI-HSA were preincubated with 300 nM NT647-labeled
factor H (Complement Technology) at 4◦C for 45min. After
preincubation, cells were washed with 1.2ml RPMI-HSA and
centrifugated (300 × g, 10min) and resuspended in 600 µl
1% (v/v) paraformaldehyde in RPMI-HSA and divided in half.
Incubation of both samples was continued at 37◦C either in the
presence or absence of 150 nM recNanA. To detect cell-bound
factor H during incubation, fluorescence intensities of the cells
were measured with BD LSR Fortessa flow cytometer (650 nm) at
different time points: 0, 2, 4, 8, 16, 32 (min). Acquired data was
analyzed with FlowJo 10.1r5 as described above.
FIGURE 1 | Removal of sialic acids from cell surfaces by RecNanA (NanA) and C. perfringens neuraminidase (Neu). 2.2 × 104 of U937 or HEK cells were incubated
with increasing concentrations (nM range) of NanA or Neu. Sialic acid removal was detected by flow cytometry using (A,B) sialic acid-specific NT647-labeled MAL-II
lectin (n = 2) or (C) galactose-specific peanut agglutinin (PNA) (n = 2). (A) Levels were calculated as relative mean fluorescence intensity of NT647-MAL-II without
neuraminidase. (B) Histogram showing distribution of MALII binding on U937 cells in the presence of 300 nM NanA, Neu or buffer. (C) Increase of FITC-PNA binding
upon removal of sialic acids was detected with increasing concentrations of NanA. (D) Sialidase activities of the purified proteins RecNanA (10 nM of NanA) and C.
perfringens neuraminidase (110 nM of Neu) and the bacterial supernatants (50%) from S. pneumoniae wild type D39 strain D39 nanA (D391nanA) mutant and the
clinical isolates. Error bars indicate SD.
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The Effect of Recnana on Pneumolysin
Mediated Hemolysis
Human blood collected in hirudin tubes was centrifugated at
650 × g for 10min at 4◦C to isolate the red blood cells. After
removing plasma cells were washed twice with ∼1.5ml ice-
cold PBS (2,000 rpm for 10min at 4◦C) and finally diluted
1:100 in PBS. Hemolysis was measured following incubation
with different concentrations (0, 5, 10, 20, and 60 nM) of
pneumolysin (PLY) from S. pneumoniae serotype two (strain D39
/ NCTC 7466) that was purchased from Cusabio (CUSABIO
TECHNOLOGY LLC, Houston, TX, US). A 2-fold (1:2)
RecNanA dilution series was prepared from 800 to 0 nM. Cells
were incubated with these different RecNanA concentrations and
a specific PLY concentration (0, 5, 10, 20, and 60 nM) in a total
volume of 50 µl for 30min at 37◦C. Hemolysis was measured
by pelleting the cells (300 × g, 10min), diluting 30 µl of the
supernatant with 70 µl PBS and measuring their absorbance at
405 nm with Labsystems iEMS Reader MF.
Statistical Measurements
Statistical significance between repeated experiments was
analyzed using one-way ANOVA pair-wise comparison
or one-way ANOVA with Tukey’s post hoc test when multiple
comparisons weremade (SPSS version 24 IBM Statistics) by using
a standard p-value threshold of <0.05 as indicating statistical
significance. Standard deviations of repeated experiments are
shown by error bars.
FIGURE 2 | Removal of sialic acids from cell surfaces by S. pneumoniae culture supernatants. 5 × 106 HEK cells were incubated with increasing volumes (% of
supernatant in total volume of the sample) of S. pneumoniae late log-phase culture supernatants from wild type D39 strain (D39 wt), D39 nanA deletion mutant
(D391NanA) and three clinical isolates (isolate 1–3). Sialic acid removal was detected by flow cytometry using (A,B) sialic acid specific NT647-labeled MAL-II lectin or
(C) by detecting free sialic-acid in the supernatant by thiobarbiturate acid at 450/532 nm. (B) Histogram showing distribution of MALII-binding on HEK cells in the
presence of supernatants from D39 wt, D391NanA and isolate 1. Levels are calculated as (A) relative mean fluorescence intensity of NT647-MAL-II without culture
supernatant (n = 3) or (C) with 1.3µM of C. perfringens neuraminidase. (D) Removal of factor H from U937 cell surface by NanA. Fluorescence intensities of U937
cells, that were preincubated with 300 nM NT647-labeled factor H, were detected with flow cytometry at different time points during incubation of the cells with or
without NanA (150 nM) (n = 3). Relative mean fluorescence intensities of the samples are shown. Statistical significance (A) against MALII binding to D391NanA cells
or (C) sialic acid release % (D) or FH binding with only medium or buffer was calculated using One-way ANOVA (*P-value < 0.05). Error bars indicate SD.
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RESULTS
S. pneumoniae RecNanA Removes Sialic
Acids From Cells
To study sialic acid removal by RecNanA from cells, increasing
concentrations of RecNanA were incubated with U937 cells.
The presence of sialic acids was detected by using NT647-
labeled MAL-II that recognizes α-2-3 linked terminal sialic
acids. Binding of NT-647-MALII was completely inhibited
after treatment of U937 cells with 30 nM of RecNanA, while
1.3µM of C. perfringens neuraminidase (Neu) was required
for the same effect (Figures 1A,B). To verify cleavage of
sialic acids from the U937 cells the exposure of terminal
galactose upon RecNanA incubation was detected using
PNA (Figure 1C). Increasing concentrations of RecNanA
resulted in a clear dose-dependent increase in PNA binding
FIGURE 3 | Removal of sialic-acid by S. pneumoniae NanA from various cells. Cultured HEK and HUVEC cells and hirudin-anticoagulated whole blood were
incubated with (A) C. perfringens neuraminidase (n = 3) and (C) S. pneumoniae culture supernatants from wild type D39 strain (D39 wt), D39 nanA deletion mutant
(D391NanA) and three clinical isolates (isolates 1–3) (n = 3). Red blood cells, peripheral blood monocytic cells, and platelets were isolated from whole blood using
double density gradient centrifugation. (B) Gating of the monocytes and lymphocytes from the peripheral blood monocytic cells are shown. (A) Sialic acid removal
from HEK and HUVEC cells and monocytes was detected by flow cytometry using sialic acid specific NT647-labeled MAL-II lectin. Levels are calculated as (A) mean
or (C) relative mean fluorescence intensity against NT647-MAL-II binding to D391NanA treated cells. Statistical significance calculated for HEK, HUVEC, red blood
cells, and peripheral blood monocytic cells (n = 3) (A) against MALII binding with only medium or (B) NT647-MAL-II binding to D391NanA cells using one-way
ANOVA (*P-value < 0.05). Error bars indicate SD.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 June 2019 | Volume 9 | Article 218
Syed et al. NanA Neuraminidase Activity in Blood
to cells indicating that sialic acids were released from
the cells.
To determine the sialidase activities of the purified proteins
and the bacterial supernatants used in this study we performed a
fluorogenic neuraminidase assay using 2
′
-(4-Methylumbelliferyl)
-α-D-N-acetylneuraminic acid (MUAN) as a substrate. The
sialidase activities of RecNanA (NanA) and C. perfringens
neuraminidase (Neu) were consistent with the NT-647-MALII
assay showing at least 10-fold higher activity for RecNanA than
Neu (Figure 1D).
NanA in S. pneumoniae Culture
Supernatant Cleaves Sialic Acids From
Cell Surfaces
To study whether released NanA is enzymatically active HEK
cells were incubated with S. pneumoniae culture supernatants
from two laboratory strains, a wild type D39 strain and its nanA
mutant. Because all S. pneumoniae strains are known to express
NanA, sialic acid removal by culture supernatants was studied
also from three clinical S. pneumoniae isolates (King et al., 2005).
The wild type D39 strain (D39 wt) and all three clinical isolates
showed a significant reduction in NT647-MALII binding, when
compared to the D39 nanA (D391nanA) mutant indicating that
NanA is active in the full bacterial secretome (Figures 2A,B).
Moreover, incubation of the cells with the supernatants from
three clinical isolates resulted in gradually elevated levels of
free sialic acids when compared to the background sample with
medium only (Figure 2C). Because FH is known to bind to
sialic acids we next studied whether removal of sialic acids
by NanA reduces binding of FH on the U937 cells. Here, a
significant reduction of FH on cell surfaces could be detected after
a 15min incubation with NanA when compared to the buffer
control (Figure 2D).
Because of the known variation of sialic acid expression on
different cell types (Nissila et al., 2018) we next studied the ability
of neuraminidase and S. pneumoniae culture supernatants to
cleave sialic acids from different cell lines (HUVEC, HEK-293T)
FIGURE 4 | Effect of S. pneumoniae NanA expression on platelet activation and aggregation. (A–C) Bacterial culture supernatants from S. pneumoniae D39 wild type
(D39 wt), D39 mutant and three clinical isolates (isolate 1–3) were incubated in citrate anticoagulated whole blood. (A) Activation of platelets was detected by
analyzing the expression of CD62P (P-selectin) by flow cytometry (n = 3). Intensity levels are calculated as relative mean fluorescence intensity against CD62P
expression by D391NanA supernatant treated cells. (B) A histogram showing distribution of CD62P-binding on platelets in the presence of supernatants from D39
wt, D391NanA and isolate 1. (C) Gating of platelets using anti-CD41a antibody. (D) To detect platelet aggregation platelets were isolated and the samples were
treated with hirudin plasma after 10min incubation with bacterial supernatant (n = 3). Aggregation of platelets was determined by subtracting the absorbance values
at 0 time point from the absorbance values at the end time point shown in (E). Statistical significances are calculated against (A) CD62P expression or (D) aggregation
between D391NanA and D39 wild type supernatant treated cells using one-way ANOVA (*P-value <0.05). Error bars indicate SD.
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and human cells (monocytes, lymphocytes, red blood cells)
and platelets in peripheral blood. Incubation of HEK and
HUVEC cells in growth medium with 2µM of C. perfringens
neuraminidase resulted in removal of sialic acids (Figure 3A)
when compared to cells that were incubated in growth medium
only. Also isolated red blood cells and monocytes showed
a slight reduction in their surface sialic acid content after
incubation with the enzyme (2µM). The S. pneumoniae culture
supernatant from D39 wild type strain removed surface sialic
acids from HUVEC cell lines as well as from monocytes and
lymphocytes in whole blood (Figure 3C), while no cleavage of
sialic acids could be detected by the supernatant from D39
nanA mutant. Moreover, S. pneumoniae culture supernatants
from the clinical isolates 1 and 2 removed sialic acids from
monocytes and lymphocytes in whole blood while only isolate
2 showed significant removal of sialic acids from HUVEC cells
and only isolate 1 showed significant removal of sialic acids
from red blood cells. These results suggest that the release of
NanA by S. pneumoniae is able to remove terminal sialic acids
from various cell types in whole blood in the presence of whole
bacterial secretome.
S. pneumoniae NanA Increases Platelet
Aggregation in Whole Blood
Disturbed recognition of sialic acids by factor H on endothelial
cells and platelets is considered to be the key mechanism causing
direct complement attack against these cells and contribute to
thrombotic microangiopathy in aHUS (Hyvarinen et al., 2016).
Therefore, we next determined the role of sialic acid removal by S.
pneumoniae NanA in the activation and aggregation of platelets
in whole blood. When sodium citrate anticoagulated whole
blood was incubated with S. pneumoniae culture supernatants
from D39 wt, D39 nanA mutant (D39 1NanA) and three
clinical isolates no significant increase in CD62P expression
was observed between the strains (Figures 4A–C). However, we
observed a significant increase in platelet aggregation by culture
supernatants from D39 wt when compared to the aggregation by
supernatant from D39 1NanA strain (Figures 4D,E) indicating
that desilaylation by NanA has a role in platelet aggregation.
S. pneumoniae NanA Increases
Complement and Pneumolysin-Mediated
Hemolysis in Whole Blood
A common clinical presentation in aHUS is intravascular
hemolysis that is induced by complement attack against
autologous cells. Therefore, we next determined the role of sialic
acid removal by NanA in red blood cell lysis and complement
activation ex vivo in whole blood. Incubation of hirudin-
anticoagulated blood with supernatants of S. pneumoniae
D39 wild type (D39 wt) and one clinical S. pneumoniae
isolate resulted in a significant increase in plasma hemoglobin
(Figure 5A), while no increase could be detected with the
supernatant of the D39 1NanA. Similarly, incubation of
supernatant of D39 wt in whole blood showed a significant
increase in plasma SC5b-9 when compared to the sample
incubated with supernatant of the D39 1NanA (Figure 5B).
In addition, incubation of supernatant of S. pneumoniae
clinical isolate 2 resulted in a significant increase in plasma
FIGURE 5 | Effect of S. pneumoniae NanA expression on complement-mediated red blood cell lysis. (A) Hirudin-anticoagulated whole blood was incubated for 1 h at
37◦C with the supernatants from S. pneumoniae D39 wild type (D39 wt), D39 nanA deletion mutant (D391NanA) and three clinical isolates (isolates 1–3). Hemolysis
was determined by measuring absorbance of hemoglobin at 405 nm from the plasma (n = 3). (B) Complement activation in whole blood was determined by
measuring the formation of soluble SC5b-9 from blood isolated plasma by EIA (450 nm) (n = 3). All values are shown as a percentage of A450 values relative to D39
nanA mutant strain. Increase in SC5b-9 is calculated as relative absorbance against D391NanA supernatant treated blood that was 0.500 ± 0.150 at 450 nm in the
isolated plasma. (C) Effect of NanA on hemolysis caused by pneumolysin (PLY). Red blood cells were incubated with increasing concentration of NanA compared with
specific PLY concentration (0, 5, 10, 20, or 60 nM). Hemolysis was detected by measuring absorbance of the supernatant at 405 nm. Absorbances for different PLY
concentrations (0–60 nM) are shown (n = 4). Saponin was used as a positive control and sample without PLY as negative control (0 nM PLY) for red blood cell
hemolysis. Statistical significances are calculated against (A,B) D391NanA supernatant treated blood (C) or between the highes and lowest NanA concentration
using one-way ANOVA (*P-value <0.05). Error bars indicate SD.
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SC5b-9. These results indicate that the expression of NanA
by S. pneumoniae increases complement-mediated hemolysis.
Although, we could detect significant differences between the
hemolytic activities of S. pneumoniae D39 wild type (D39 wt)
and D39 1NanA supernatants, we could not rule out the
possibility that NanA could have an effect on pneumolysin
mediated hemolytic activity as well. Therefore, we next
performed a hemolysis assay in the presence of pneumolysin and
increasing concentrations of NanA. A dose dependent increase
in pneumolysin mediated hemolysis could be detected in the
presence of increasing concentrations of NanA while NanA itself
did not cause any hemolysis (Figure 5C). However, in limited
pneumolysin concentrations (below 20 nM) no dependence on
NanA concentrations on pneumolysin mediated hemolysis could
be detected.
DISCUSSION
Pneumococcal HUS is one of the most severe complications
of invasive pneumococcal disease (Janapatla et al., 2013).
Pneumococcal neuraminidase activity has been suggested to
trigger pHUS (Coats et al., 2011) but it is unclear whether
expression of neuraminidase correlate with HUS disease
pathology (Janapatla et al., 2013; Smith et al., 2013; Singh et al.,
2016). In this study, we demonstrate that the presence of NanA
increases the ability of S. pneumoniae to cleave sialic acids from
host cells in the presence of whole blood and whole bacterial
secretome. Removal of host sialic acids from host cells by the
enzyme resulted in complement activation in blood plasma,
enhanced platelet aggregation and hemolysis ex vivo.
Here, 30 nM of S. pneumoniae RecNanA was required to
remove nearly 100% of sialics from cell surfaces (Figure 1).
The C. perfringens neuraminidase is known to reduce sialic
acid recognition by factor H on self cells (Nissila et al., 2018)
indicating that NanA can potentially disturb this interaction at
low expression levels and thereby trigger AP activation against
self cells and lead to thrombosis and hemolysis in a similar
mechanism as in aHUS (Hyvarinen et al., 2016).
NanA has the potential of cleaving sialic acids from various
cell types (Klein et al., 1977; Parker et al., 2009; Smith et al.,
2013) and, as shown here, also in the presence of whole blood
and the whole bacterial secretome (Figures 2, 3). It is known that
host proteins contain N-glycan structures and therefore removal
of sialic acids by NanA could also alter the function of these
proteins in our ex vivo assay (King et al., 2004). However, this
would probably not affect the function of factor H, as N-linked
glycans in factor H have structural rather than functional roles in
the interactions between factor H and its natural binding partners
(Fenaille et al., 2007).
In HUS pathogenesis, platelet activation, endothelial cell
damage, and hemolysis are considered hallmarks of the disease.
In pHUS the morbidity and mortality is higher than in classical
STEC-HUS having also a poorer long-term prognosis (Smith
et al., 2013). This indicates that microbial virulence factors
contribute to the severity of the disease. In our hands the presence
of NanA produced by the D39 strain efficiently removed sialic
acids and led to complement activation, platelet aggregation and
hemolysis in whole blood when compared to the NanA deletion
mutant. Although this was not that evident with the studied
clinical isolate supernatants it has been previously shown that
exposure of platelets to soluble NanA leads to platelet hyper
reactivity (Kullaya et al., 2018).
All clinical isolates tested express NanA, but according to
previous studies the expression or activity of this enzyme does
not correlate with the disease state (Singh et al., 2016). All the
supernatants from clinical isolates were able to remove sialic
acids from cells. Incubation of whole blood with the supernatants
from clinical isolates 1 and 2 resulted in a significant increase
in complement activation that was detected as an increase in
soluble C5b-9 in the isolated plasma. According to our results it is
evident that the presence of NanA is crucial for the pathogenetic
effects in our ex vivo model as it allows the carrier strain to
FIGURE 6 | Schematic illustration of the putative mechanism how NanA could reduce complement regulation by factor H on the cells and sensitize cells for attack by
complement and thereby lead to cell damage. In addition, NanA could increase the susceptibility of cells to attack by pneumolysin (PLY) or other virulence factors.
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remove sialic acids, activate complement and platelets, and
cause hemolysis.
A potent cytolysin of S. pneumoniae is pneumolysin (Bokori-
Brown et al., 2016). It is a cholesterol dependent pore-forming
toxin known to be expressed by all S. pneumoniae strains
(Kanclerski and Mollby, 1987). Therefore, it is possible that
hemolysis observed in our assays could have partially been
caused by this toxin. In this study we observed that NanA could
alter the lytic activity of the toxin on self cells. The reason for
this could be that the recognition of cells by pneumolysin is
partially dependent on specific cell exposed glycan structures
(Shewell et al., 2014). The supernatant from the nanA mutant
strain did not, however, lead to hemolysis in whole blood
indicating that the hemolysis was at least partially caused by
complement directed against desialylated self cells especially
because removal of sialic acids reduced binding of factor H on
self cells. Surprisingly, incubation of the supernatant from isolate
1 did not cause hemolysis in whole blood although it showed high
sialidase activity on the studied cells. Therefore, we cannot rule
out the possibility that increased susceptibility to complement-
mediated hemolysis could have been caused by other factors
than the neuraminidase enzyme. Previous studies have shown
that Thomsen-Friedenreich antigen is exposed upon treatment
with neuraminidase, particularly with NanA (Coats et al., 2011).
Exposure of this antigen can lead to agglutination of erythrocytes
and may thereby accelerate hemolysis (McGraw et al., 1989) and
clearance of erythrocytes and platelets (Crookston et al., 2000;
Coats et al., 2011; Janapatla et al., 2013).
Based on our results it is likely that NanA is crucial for
sialidase activity against cells as the supernantant from nanA
deletion mutant showed no increase in plasma C5b-9 that was
isolated from supernatant incubated whole blood. This could be
due to the broad sialic acid specificity of NanA that can cleave
terminal sialic acids with α2–3, α2–6, and α2–8 linkages (Xu et al.,
2011). Altough, NanB cleaves α2–3, α2–6, and α2–8, it has more
activity on α2–3 while NanC is specific only for α2–3 linkages (Xu
et al., 2008; Owen et al., 2015). Interestingly, the only sialic acid
binding site in factor H domain 20 interacts with α2-3-sialylated
glycans but the protein itself is α2-3- and α2-6-sialylated in a ratio
of 8.5 and 91.5%, respectively (Blaum et al., 2015; Schmidt et al.,
2018). Thereby, NanA could also act on factor H sialic acids and,
speculatively, reduce stability of factor H.
Increase in complement activation in whole blood by the
bacterial supernatant was detected from plasma that was isolated
from whole blood after incubation with the supernatants. Soluble
C5b-9, that is a byproduct of complement activation, was used as
a marker for complement activation. Because of the significant
correlation between NanA expression and increase in blood
isolated plasma C5b-9 these results suggest that NanA increases
complement activity in whole blood by cleaving sialic acids
from cell surfaces and predisposes sensitized red blood cells
for complement and pneumolysin mediated lysis and platelets
for aggregation (Figure 6). Thereby, NanA could contribute to
pHUS pathogenesis. This effect could be especially strong in
individuals with predisposing genetic variants in complement
genes such as CFH and CFI (Szilagyi et al., 2013).
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